Laxmi Organic Industries is a chemical manufacturer that has spent three decades moving steadily up the value chain - from making simple industrial solvents to producing complex molecules that go inside medicines and crop-protection chemicals. Founded in 1989 by chemical engineer Ravi Goenka, it started with a single plant making ethyl acetate and has since expanded by buying technology and assets from global players like Clariant and Miteni of Italy, relocating and scaling them in India. The recurring approach is to master a chemistry platform at large volumes, then use the cash and customer relationships it generates to fund the next, more specialised chemistry - a ladder the company climbed from acetylation to diketene derivatives and now to fluorination.
Business segments
Two engines at different stages - a high-volume acetyl-intermediates cash cow and a higher-margin specialties platform built on diketene and fluorine chemistry - each feeding the other with shared raw materials, customers and cash flows.
1. Essentials: the industrial-scale backbone that funds everything else
The Essentials business makes large-volume solvents and intermediates on a cost-leadership model, where the company is India’s largest supplier of ethyl acetate and the country’s biggest exporter of acetyl intermediates to Europe.
- The raw-material spread is the profit engine - it buys alcohols, acetic acid and ethanol, converts them into products like ethyl acetate and acetic anhydride, and manages a 30-to-45-day lag between raw-material costs and finished-goods prices, which is how it protects its margin.
- Location does the heavy lifting - the main plant at Mahad sits near three major ports (Nhava Sheva, JSW and Mumbai), and the company keeps finished-product storage tanks in Rotterdam, Antwerp and Genoa, so European customers get just-in-time delivery without the company needing a factory there.
- Backward integration where it counts - two in-house distilleries in Maharashtra turn molasses from nearby sugar mills into ethanol, giving the company a captive supply of a key raw material and making it one of the largest suppliers of fuel-grade ethanol to India’s oil-marketing companies.
- Scale that competitors are walking away from - with the single largest ethyl-acetate site in India and a new world-scale line at Lote that started shipping in May 2026, the company is adding capacity at a time when it says rivals are idling or exiting at current margin levels.
2. Specialties: the higher-margin engine built on diketene and fluorine chemistry
The Specialties business makes niche intermediates that go into pharmaceuticals, agrochemicals and pigments - products with no drop-in substitutes, where the company is the largest domestic player and among the top five globally in diketene derivatives.
- Bought, not just built - the business was launched in 2011 and scaled by acquiring the ketene and diketene portfolio of Clariant’s Indian operations in 2012 (16 products), then adding twenty more products and nearly tripling capacity over the following decade.
- Fluorine is the new leg - the company bought the plant, patents and REACH registrations of Miteni, an Italian fluorospecialties maker, dismantled the equipment and reinstalled it at Lote in Maharashtra, giving it a chemistry platform that no other Indian player currently manufactures.
- The same customers, a deeper wallet - up to 20% of pharma molecules and half of recently developed agrochemical molecules contain a fluorine atom, and the company already sells to pharma and agro customers through its diketene business, so the fluorospecialties range is sold into relationships it already has.
- A phased ramp-up with room to run - the fluorination unit at Lote reached 40-45% of its peak revenue in FY26 and enters FY27 with a good order book, while the company is also building an R&D and kilo-lab facility in Italy to act as a front end for innovative European customers.
Technology and R&D
A shared innovation backbone that turns lab-scale chemistry into commercial plants, feeding new products into both business segments.
- Two certified R&D centres with pilot-plant muscle - a lab at the Mahad site and a 30,000 sq ft Innovation Centre in Navi Mumbai (opened in 2025 with an $8 million investment) house reactors that can run at up to 100 Bar pressure and temperatures from -20°C to 250°C, letting the company prove a process before spending on a full-scale plant.
- New products are the growth engine - the R&D team of 65-plus people has developed five chemistry platforms at commercial scale and added 34 new products to the Specialties platform in eight years, with nearly half of the Specialties vertical’s revenue coming from products synthesised by R&D.
- A pipeline, not a one-off - the company has 11 products in the pilot and capex-approval stages, and it aims for 20% of Specialties revenue to come from products launched in the last five years.
Group structure and partners
A single listed entity that has progressively simplified its structure by merging in its operating subsidiaries, while maintaining overseas stock points and a strategic renewable-energy partnership.
- The company merged its wholly owned subsidiary Acetyls Holding and its step-down Yellowstone Chemicals into itself in 2022, and then merged Yellowstone Fine Chemicals (which held the Lote fluorospecialties plant) into itself in 2025, so all manufacturing assets now sit directly on the listed company’s books.
- It maintains offices in Amsterdam and Shanghai and tank operations in Antwerp and Genoa, giving it a direct physical presence in its key export markets.
- The company holds a 26% stake in a special-purpose vehicle that generates renewable energy and supplies it on a captive basis, and it signed a five-year global sourcing agreement with Hitachi Energy in 2025 to supply an eco-efficient gas for SF6-free high-voltage switchgear, committing roughly ₹75 crores in capex.